# Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

> **NCT00935532** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 427 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** exenatide once weekly
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT00935532
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-09
- **Final completion:** 2011-07
- **Target enrollment:** 427 (ACTUAL)
- **Last updated:** 2015-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00935532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00935532, "Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00935532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*